STERIS plc FY2026 (Ended March 31, 2026): Broad-Based Growth Drives 27% Operating Income Expansion

• Revenue increased $476.4 million to $5,935.9 million (+8.7%), driven by mid-single digit volume growth and low-single digit pricing gains across Healthcare, AST, and Life Sciences, with $74.4 million from favorable foreign exchange movements.

• Operating income surged 27.1% to $1,101.8 million from $866.6 million, primarily due to pricing, volume, productivity gains, and $42 million lower restructuring costs (from $46M to $4.1M), partially offset by tariffs and inflation.

• Free cash flow increased to $982.9 million from $787.2 million (+24.8%), driven by stronger net income outweighing reduced working capital benefits, while capital allocation included $225 million in share repurchases, $241.8 million in dividends ($2.46/share vs $2.23/share), and a new $1 billion repurchase program authorized May 2026.

STERIS reported revenue growth of 8.7% to $5.9 billion, with all three segments expanding: Healthcare up 8.5% to $4.2 billion, AST up 9.6% to $1.1 billion, and Life Sciences up 8.6% to $588.8 million. Constant currency organic growth ranged from 6.7% to 7.6% across segments, driven by mid-single digit volume gains and low-single digit pricing improvements. The Dental segment, divested in May 2024 for $787.5 million, is now classified as discontinued operations. Gross margin expanded modestly to 44.2% from 44.0%, as pricing (+120 basis points), operational improvements (+70 basis points), and productivity (+50 basis points) offset tariffs (-80 basis points), inflation (-70 basis points), and material costs (-30 basis points). Operating income increased 27.1% to $1.1 billion, with the company substantially completing its targeted restructuring plan that incurred $4.1 million in charges versus $46 million in the prior year. Selling, general, and administrative expenses rose 5.5% to $1.4 billion, reflecting higher compensation and bad debt expense, while R&D increased 4.9% to $112.9 million. Net cash from operations rose 16.8% to $1.3 billion, and free cash flow climbed to $982.9 million, aided by stronger earnings despite weaker working capital contribution. The company ended fiscal 2026 with a debt-to-total capital ratio of 21.3%, down from 23.6%, after repaying $125 million in Private Placement Senior Notes.

The 27% surge in operating income marks a significant inflection in profitability, demonstrating improved operating leverage and the payoff from restructuring efforts. With restructuring charges declining 91% from $46 million to $4.1 million, and the Dental segment divestiture allowing management to focus on core infection prevention and sterilization businesses, STERIS is demonstrating clearer earnings quality. The combination of volume and pricing gains across all segments suggests the company is successfully navigating competitive dynamics while managing cost pressures. The 46.1% operating margin in the AST segment (up 130 basis points) is particularly notable given the EO litigation overhang and reflects strong pricing discipline and volume capture. The 24.8% increase in free cash flow to $982.9 million supports capital allocation flexibility-dividends increased 10.3% per share, share repurchases totaled $225 million under the outgoing program, and a new $1 billion repurchase authorization signals confidence. However, the Healthcare segment's margin compression (24.6% vs 25.0%) due to tariffs and inflation highlights the need to watch cost mitigation efforts. The 25% effective tax rate (up from 23.2%) reflects geographic mix changes and discrete withholding taxes, adding some headwind to earnings growth. Overall, the results point to a business that is gaining operational momentum, but investors should monitor tariff impacts, EO litigation developments, and the company's ability to sustain pricing power amid inflation.

STERIS generated revenue of $5.9 billion (+8.7%) with operating income of $1.1 billion (+27.1%), driven by volume and pricing gains across Healthcare, AST, and Life Sciences segments. The Healthcare segment posted $4.2 billion in revenue (+8.5%) with service revenue growth of 11.8%, though operating margin compressed to 24.6% due to tariffs and inflation. AST segment revenue reached $1.1 billion (+9.6%) with operating margin expanding to 46.1%, reflecting strong pricing. Life Sciences revenue totaled $588.8 million (+8.6%) with operating margin at 42.6%. Gross margin improved to 44.2% from 44.0%, benefiting from pricing (+120 bps) and productivity (+50 bps), partially offset by tariffs (-80 bps) and inflation (-70 bps). Restructuring charges declined 91% to $4.1 million as the restructuring plan neared completion. Free cash flow increased to $982.9 million from $787.2 million, enabling $241.8 million in dividends ($2.46/share) and $225 million in share repurchases. Debt-to-total capital improved to 21.3% from 23.6%. Capital expenditures remained stable at $369 million. The company divested the Dental segment for $787.5 million and acquired two tuck-in businesses for $23.4 million, while investing $134 million in a noncontrolling equity stake in a non-U.S. healthcare manufacturer. A new $1 billion share repurchase program was authorized in May 2026.

Management indicated that the company continues to benefit from the aging global population driving increased demand for medical procedures, preventive screenings, and operational efficiency among customers. The company stated it expects to manage costs, grow through internal product and service development, invest in greater capacity and efficiency, and augment value creation with potential acquisitions in fiscal 2027 and beyond. Management highlighted that the restructuring plan, which eliminated approximately 300 positions, is substantially complete and has begun delivering profitability enhancements and efficiency improvements in fiscal 2025 and 2026. The company noted it is investing in facility expansions, particularly within Healthcare and AST segments, and commencing a multi-year project to upgrade technology supporting service and sales workflows in Healthcare and Life Sciences segments. On the Illinois EO litigation, management confirmed settlement agreements were entered to resolve substantially all personal injury claims pending in Cook County, though a claims process is ongoing and subject to final court approval. Management emphasized the company maintains adequate property, casualty, and liability insurance, though acknowledged no assurance can be given that policies will provide adequate protection against all potential risks.

The company faces significant risks from ongoing EO litigation, with settlement agreements subject to final court approval and potential for future claims that could exceed insurance coverage. Tariff and inflation pressures negatively impacted gross margin by 150 basis points combined, and future trade policy changes or supply chain disruptions could further compress margins or limit product availability. The effective tax rate increased to 25.0%, and future tax law changes, including evolving GloBE rules and changes to international tax treaties, could materially increase the consolidated tax burden. The company relies on limited suppliers for critical materials such as cobalt-60 and EO, and shortages or price increases could adversely affect AST operations. Regulatory changes regarding EO use could curtail or eliminate contract sterilization operations, with material adverse effects on financial condition and results of operations. The company is exposed to cybersecurity threats that could disrupt operations, compromise customer data, or result in material liabilities. Consolidation among healthcare and pharmaceutical customers may result in pricing pressures or customer loss. The company's debt level and access to credit markets may limit financial flexibility, with approximately $1.9 billion of indebtedness outstanding. Climate change regulations and sustainability reporting requirements, including CSRD and ESRS, are increasing compliance complexity and costs. Geopolitical instability, including conflicts and trade policy changes, could disrupt supply chains, increase costs, or reduce demand. Integration of acquired businesses and realization of expected synergies remain uncertain. Goodwill and intangible assets totaling approximately $6 billion could become impaired, resulting in material non-cash charges.

Investors should monitor:

• Healthcare segment margin trajectory given tariff and inflation headwinds compressed margins by 40 basis points in FY26; ability to sustain pricing discipline and offset cost pressures through productivity will be critical.

• Final resolution and court approval of Illinois EO litigation settlement, including whether all eligible claimants participate and whether the company exercises any walkaway rights, as future liabilities could exceed the $48.2 million settlement amount.

• Impact of evolving trade policies and tariffs on cost structure and supply chain, particularly given the company's global manufacturing footprint and potential need for material changes requiring significant capital expenditures or asset impairments.

• Progress on multi-year technology investment to support service and sales workflows in Healthcare and Life Sciences segments, and whether these investments deliver anticipated operational efficiencies and revenue growth.

• AST segment's ability to sustain pricing gains that contributed to 130 basis point margin expansion, particularly as customers may consider in-sourcing sterilization needs or as competitive pressures intensify.